191 related articles for article (PubMed ID: 29403383)
1. How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.
Schleim S; Quednow BB
Front Pharmacol; 2018; 9():3. PubMed ID: 29403383
[TBL] [Abstract][Full Text] [Related]
2. Smart drugs "as common as coffee": media hype about neuroenhancement.
Partridge BJ; Bell SK; Lucke JC; Yeates S; Hall WD
PLoS One; 2011; 6(11):e28416. PubMed ID: 22140584
[TBL] [Abstract][Full Text] [Related]
3. The is and ought of the Ethics of Neuroenhancement: Mind the Gap.
Forlini C; Hall W
Front Psychol; 2015; 6():1998. PubMed ID: 26779100
[TBL] [Abstract][Full Text] [Related]
4. Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background.
Weiergräber M; Ehninger D; Broich K
Med Monatsschr Pharm; 2017 Apr; 40(4):154-64. PubMed ID: 29952165
[TBL] [Abstract][Full Text] [Related]
5. On pharmacological neuroenhancement as part of the new neurorights' pioneering legislation in Chile: a perspective.
Cornejo-Plaza MI; Saracini C
Front Psychol; 2023; 14():1177720. PubMed ID: 37533709
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological neuroenhancement and brain doping : Chances and risks].
Franke AG; Lieb K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):853-9. PubMed ID: 20700786
[TBL] [Abstract][Full Text] [Related]
7. Cognitive neuroenhancement: false assumptions in the ethical debate.
Heinz A; Kipke R; Heimann H; Wiesing U
J Med Ethics; 2012 Jun; 38(6):372-5. PubMed ID: 22228818
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Neuroenhancement in the Field of Economics-Poll Results from an Online Survey.
Dietz P; Soyka M; Franke AG
Front Psychol; 2016; 7():520. PubMed ID: 27148128
[TBL] [Abstract][Full Text] [Related]
9. "It Was Me on a Good Day": Exploring the Smart Drug Use Phenomenon in England.
Vargo EJ; Petróczi A
Front Psychol; 2016; 7():779. PubMed ID: 27303339
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of and motives for pharmacological neuroenhancement in Switzerland--results from a national Internet panel.
Maier LJ; Haug S; Schaub MP
Addiction; 2016 Feb; 111(2):280-95. PubMed ID: 26189457
[TBL] [Abstract][Full Text] [Related]
11. [Neuroenhancement].
Gründer G; Bartsch T
Nervenarzt; 2014 Dec; 85(12):1536-43. PubMed ID: 25403289
[TBL] [Abstract][Full Text] [Related]
12. How cognitive enhancement can change our duties.
Santoni de Sio F; Faulmüller N; Vincent NA
Front Syst Neurosci; 2014; 8():131. PubMed ID: 25100952
[TBL] [Abstract][Full Text] [Related]
13. Bottom Up Ethics - Neuroenhancement in Education and Employment.
Bard I; Gaskell G; Allansdottir A; da Cunha RV; Eduard P; Hampel J; Hildt E; Hofmaier C; Kronberger N; Laursen S; Meijknecht A; Nordal S; Quintanilha A; Revuelta G; Saladié N; Sándor J; Santos JB; Seyringer S; Singh I; Somsen H; Toonders W; Torgersen H; Torre V; Varju M; Zwart H
Neuroethics; 2018; 11(3):309-322. PubMed ID: 30220937
[TBL] [Abstract][Full Text] [Related]
14. Neuroethical issues in cognitive enhancement: Modafinil as the example of a workplace drug?
Brühl AB; d'Angelo C; Sahakian BJ
Brain Neurosci Adv; 2019; 3():2398212818816018. PubMed ID: 32166175
[TBL] [Abstract][Full Text] [Related]
15. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review.
Repantis D; Schlattmann P; Laisney O; Heuser I
Pharmacol Res; 2010 Sep; 62(3):187-206. PubMed ID: 20416377
[TBL] [Abstract][Full Text] [Related]
16. [Neuroenhancement in healthy subject? A French case study].
Micoulaud-Franchi JA; Vion-Dury J; Lancon C
Therapie; 2012; 67(3):213-21. PubMed ID: 22874487
[TBL] [Abstract][Full Text] [Related]
17. [Options, limits and ethics of pharmacological neuroenhancement].
Normann C; Boldt J; Maio G; Berger M
Nervenarzt; 2010 Jan; 81(1):66-74. PubMed ID: 19851745
[TBL] [Abstract][Full Text] [Related]
18. Neuroenhancement as Instrumental Drug Use: Putting the Debate in a Different Frame.
Schleim S
Front Psychiatry; 2020; 11():567497. PubMed ID: 33088276
[TBL] [Abstract][Full Text] [Related]
19. Neuroenhancement: status quo and perspectives.
Normann C; Berger M
Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():110-4. PubMed ID: 18985306
[TBL] [Abstract][Full Text] [Related]
20. Neuroenhancement: State of the Art and Future Perspectives.
Marazziti D; Avella MT; Ivaldi T; Palermo S; Massa L; Vecchia AD; Basile L; Mucci F
Clin Neuropsychiatry; 2021 Jun; 18(3):137-169. PubMed ID: 34909030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
